Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T J Lobl

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Steroids|September 1, 1981
Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP)G R Cunningham, D J Tindall, T J Lobl, et al.
The Journal of Biological Chemistry|September 25, 1993
A novel cyclic pentapeptide inhibits alpha 4 beta 1 and alpha 5 beta 1 integrin-mediated cell adhesionD M Nowlin, F Gorcsan, M Moscinski, et al.
Journal of Biochemistry|September 1, 1989
Characterization of monoclonal antibodies against human prorenin profragment and identification of active prorenins in plasmaY Ishizuka, S Iizumi, F Akiyama, et al.
Contraception|April 1, 1983
Contraceptive efficacy of testosterone-estradiol implants in male rhesus monkeysT J Lobl, K T Kirton, A D Forbes, et al.
The Journal of Biological Chemistry|July 15, 1994
Cyclic RGD peptide inhibits alpha 4 beta 1 interaction with connecting segment 1 and vascular cell adhesion moleculeP M Cardarelli, R R Cobb, D M Nowlin, et al.
International Journal of Cancer|March 15, 1989
Use of the Membrane Invasion Culture System (MICS) as a screen for anti-invasive agentsD R Welch, T J Lobl, E A Seftor, et al.
Cancer Research|April 18, 2001
Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studiesA Trouet, A Passioukov, K Van derpoorten, et al.
FEBS Letters|August 4, 1998
Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesisS A Steitz, K Hasegawa, S L Chiang, et al.
Journal of Medicinal Chemistry|October 19, 2001
N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicityA M Fernandez, K Van Derpoorten, L Dasnois, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Steroids|September 1, 1981
Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP)G R Cunningham, D J Tindall, T J Lobl, et al.
The Journal of Biological Chemistry|September 25, 1993
A novel cyclic pentapeptide inhibits alpha 4 beta 1 and alpha 5 beta 1 integrin-mediated cell adhesionD M Nowlin, F Gorcsan, M Moscinski, et al.
Journal of Biochemistry|September 1, 1989
Characterization of monoclonal antibodies against human prorenin profragment and identification of active prorenins in plasmaY Ishizuka, S Iizumi, F Akiyama, et al.
Contraception|April 1, 1983
Contraceptive efficacy of testosterone-estradiol implants in male rhesus monkeysT J Lobl, K T Kirton, A D Forbes, et al.
The Journal of Biological Chemistry|July 15, 1994
Cyclic RGD peptide inhibits alpha 4 beta 1 interaction with connecting segment 1 and vascular cell adhesion moleculeP M Cardarelli, R R Cobb, D M Nowlin, et al.
International Journal of Cancer|March 15, 1989
Use of the Membrane Invasion Culture System (MICS) as a screen for anti-invasive agentsD R Welch, T J Lobl, E A Seftor, et al.
Cancer Research|April 18, 2001
Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studiesA Trouet, A Passioukov, K Van derpoorten, et al.
FEBS Letters|August 4, 1998
Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesisS A Steitz, K Hasegawa, S L Chiang, et al.
Journal of Medicinal Chemistry|October 19, 2001
N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicityA M Fernandez, K Van Derpoorten, L Dasnois, et al.
Pageof 3